The Defense Health Agency awarded a $498,896 Project Grant through the Military Medical Research and Development program (CFDA 12.420) to The Schepens Eye Research Institute, Inc. in Boston, MA. The grant supports a 2-year research project investigating the use of noninvasive transpalpebral electrical stimulation as a therapy for combat-related corneal trauma. As an experienced performer of prior federal grants from agencies like the NIH, DoD, and Army, the non-profit Schepens Eye Research...
The Schepens Eye Research Institute, Inc. was awarded a $1,477,390.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on June 15, 2023, will fund research to investigate the role of the Rho-kinase pathway in proliferative vitreoretinopathy, a serious eye condition, over a 3-year period ending on June 14, 2026. As a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,477,500 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The 3-year grant, awarded on September 1, 2023, will fund research on "Topical Calcitonin Gene-Related Peptide for Corneal Injury Prevention and Regeneration." The Schepens Eye Research Institute, which has...
The Schepens Eye Research Institute, Inc. was awarded a $1,475,676 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 1, 2022 to August 31, 2025 to develop concomitant topical treatments for pain and inflammation resulting from ocular injuries. The Military Medical Research and Development program supports biomedical research that transforms military and public health...
The Department of the Army Medical Command awarded a $1,428,860 Project Grant to The Schepens Eye Research Institute, Inc. of Boston, MA under the Military Medical Research and Development program (CFDA 12.420) to investigate the safety and efficacy of supersaturated oxygen emulsion (SSOE) as a novel topical treatment for open globe injury. The three-year award beginning September 30, 2022 will support animal research using mice to test SSOE and controls supplied by sub-awardee Coruna Medical...
The Department of Defense's Defense Health Agency awarded a $820,833 Project Grant to The Schepens Eye Research Institute, Inc., a non-profit research organization affiliated with Harvard Medical School and Massachusetts Eye and Ear. The grant, funded through the Military Medical Research and Development program (CFDA 12.420), supports a research project to "Identify the Liver Microenvironment that Drives Uveal Melanoma Metastasis and Immunity." The 3-year award, effective from...
The $309,086 Project Grant awarded by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Centre for Eye Research Australia Limited (operating as the University of Melbourne Department of Ophthalmology) to target NADPH oxidase 4 to reduce ocular scarring following chemical burns to the eye. The project will run from July 2025 to June 2027 and aims to develop innovative medical treatments to address this critical eye...
The Johns Hopkins University received a $5,553,561 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on using retinal ganglion cell (RGC) transplantation as a treatment for traumatic brain injury (TBI)-related optic nerve injury. The grant period runs from August 1, 2023 to July 31, 2027. As a sub-award under this grant, the Schepens Eye Research Institute, Inc., a non-profit Harvard Medical School...
The Department of Defense's Defense Health Agency awarded a $1,158,179.00 Project Grant to The Ohio State University under the Military Medical Research and Development program (CFDA 12.420) to deliver a sustained therapeutic protein cocktail delivery system to prevent vision loss after ocular trauma. The project aims to develop innovative treatments for military service members and veterans by conducting basic, translational, and clinical research. As a sub-award under this grant, the...
This $1,622,955 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research and development of a novel therapeutic agent called LACRIPEP for corneal wound healing and ocular surface homeostasis. The grant was awarded on September 15, 2024 to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., a non-profit research organization, with a performance period ending on September 14,...